(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Old video misrepresented as senior Sri Lankan ruling party member criticising president over fuel shortage - 26 Tire Brands Reasonable for Seniors
- 3Rubble, mud and hair: How to rebuild a home in Gaza
- 4Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- 5Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- The Way to Monetary Freedom: A Viable Aide
- The Best 15 Applications for Efficiency and Association
- Five EU states press for windfall taxes on fossil energy sector
- Turkiye’s Erdogan calls Israel’s Somaliland recognition ‘unacceptable’
- Smartwatches: Remain Associated and Dynamic
- This Week In Space podcast: Episode 203 — China Rising
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- When a sperm whale gives birth, the mother gets help from her friends
- CDC pauses dozens of types of lab testing during evaluation and in wake of downsizing
